Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › NJ › Hackettstown › NPI 1518969419
Hospital

Ahs Hospital Corp

Ahs Hospital Corp was paid $16.26M by Medicaid between Jan 2018 and Dec 2024, across 174 billing codes. Its largest line is 99283, emergency room visit (moderate) — 17% of everything it billed.

33Billing provider infoAHS HOSPITAL CORP
HACKETTSTOWN, NJ 07840
33aNPI1518969419assigned 08/11/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$16.26M
24GClaims322,739
24DCodes billed174
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers

Next to other General Acute Care Hospital providers in New Jersey

Rank by total paid#57 of 93
Median peer was paid$30.60M
This provider vs. median0.5×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Auditor's notes

Automated statistical signals. Not evidence of fraud — how these are computed.

Entity ProliferationAuthorized official WALTER, JOSEPH controls 12+ related entities in our dataset. Read more
Box 24A · Dates of service

Paid by month

$0$200K$400K2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
201835,031$1.41M
201931,994$1.41M
202034,872$1.85M
202142,228$2.40M
202258,433$3.10M
202367,871$3.23M
2024incomplete52,310$2.86M
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
99283 Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity 17% 11,027 10,277 $2.75M
99284 Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity 14% 7,972 7,265 $2.27M
99285 Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life 9.2% 5,040 4,554 $1.49M
74177 Computed tomography, abdomen and pelvis; with contrast material 7.1% 2,327 2,157 $1.15M
G0378 Hospital observation service, per hour 4.9% 1,816 895 $792K
0202U Oncology (prostate), multianalyte, gene expression profiling 4.4% 5,055 4,613 $713K
97110 Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion 4.0% 19,454 4,170 $645K
93306 Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete 3.7% 543 512 $602K
97140 Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) 3.7% 12,524 2,978 $595K
96365 Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour 2.6% 4,115 2,322 $424K
96375 Therapeutic injection; each additional sequential IV push 2.5% 4,719 3,454 $411K
99282 Emergency department visit for the evaluation and management, low to moderate severity 2.3% 3,700 3,550 $375K
162 more codes
70450 Computed tomography, head or brain; without contrast material 2.2% 2,650 $357K
74176 Computed tomography, abdomen and pelvis; without contrast material 2.1% 969 $346K
97530 Therapeutic activities, direct patient contact, each 15 minutes 1.6% 2,904 $257K
93005 Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report 1.5% 8,692 $242K
90853 Group psychotherapy (other than of a multiple-family group) 1.1% 7,534 $183K
96360 Intravenous infusion, hydration; initial, 31 minutes to 1 hour <1% 1,767 $149K
85025 Blood count; complete (CBC), automated, and automated differential WBC count <1% 15,116 $135K
80053 Comprehensive metabolic panel <1% 12,662 $127K
97112 Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination <1% 3,594 $117K
77067 Screening mammography, bilateral, including computer-aided detection <1% 1,122 $113K
96374 Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance <1% 4,992 $104K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay <1% 3,252 $104K
71046 Radiologic examination, chest; 2 views <1% 3,348 $94K
71045 Radiologic examination, chest; single view <1% 4,089 $94K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed <1% 2,218 $87K
76700 Ultrasound, abdominal, real time with image documentation; complete <1% 463 $77K
96361 Intravenous infusion, hydration; each additional hour <1% 3,651 $74K
72125 Computed tomography, cervical spine; without contrast material <1% 477 $68K
76830 Ultrasound, transvaginal <1% 373 $64K
OP250 <1% 32,676 $63K
87633 Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets <1% 328 $58K
92507 Treatment of speech, language, voice, communication, and/or auditory processing disorder <1% 818 $55K
OP710 <1% 601 $51K
96372 Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular <1% 3,590 $48K
84484 <1% 5,145 $45K
77063 Screening digital breast tomosynthesis, bilateral <1% 1,113 $42K
U0003 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r <1% 602 $37K
71275 Computed tomographic angiography, chest, with contrast material <1% 156 $37K
96413 Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance <1% 138 $36K
0241U Neonatal screening for hereditary disorders, genomic sequence analysis panel <1% 927 $35K
93017 <1% 55 $32K
97162 <1% 580 $30K
OP272 <1% 6,551 $30K
11042 Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm <1% 177 $29K
36415 Collection of venous blood by venipuncture <1% 15,950 $28K
76856 Ultrasound, pelvic (nonobstetric), real time with image documentation; complete <1% 193 $28K
OP270 <1% 6,233 $27K
96376 <1% 740 $27K
97161 <1% 488 $23K
84443 Thyroid stimulating hormone (TSH) <1% 2,040 $19K
80048 Basic metabolic panel (calcium, ionized) <1% 3,242 $19K
76641 <1% 104 $18K
81001 <1% 6,541 $18K
87651 Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe <1% 1,033 $17K
81025 <1% 3,810 $15K
71250 <1% 108 $15K
83690 <1% 3,681 $14K
94640 Pressurized or nonpressurized inhalation treatment for acute airway obstruction <1% 595 $14K
71260 Computed tomography, thorax, diagnostic; with contrast material <1% 57 $13K
83735 <1% 3,665 $13K
85610 <1% 4,482 $13K
84145 <1% 921 $12K
85730 <1% 3,970 $12K
83880 <1% 1,077 $11K
73610 <1% 320 $11K
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 <1% 484 $9K
73630 <1% 263 $9K
86850 <1% 802 $8K
73030 <1% 205 $7K
99281 Emergency department visit for the evaluation and management, self-limited or minor <1% 127 $7K
87486 <1% 330 $7K
87581 <1% 330 $7K
83605 <1% 1,180 $7K
87798 Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism <1% 332 $6K
87635 Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe <1% 267 $6K
82962 <1% 2,587 $6K
87040 <1% 707 $6K
0012A <1% 209 $6K
76536 <1% 42 $6K
0011A <1% 209 $5K
96366 Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour <1% 219 $5K
OP258 <1% 5,265 $5K
0004A <1% 140 $5K
86901 <1% 854 $5K
J1756 Injection, iron sucrose, 1 mg <1% 136 $5K
OP259 <1% 2,921 $5K
80076 <1% 1,144 $4K
86900 <1% 864 $4K
84702 <1% 434 $4K
87631 <1% 59 $4K
87086 Culture, bacterial; quantitative colony count, urine <1% 899 $3K
85378 <1% 895 $3K
80061 Lipid panel <1% 636 $3K
73564 <1% 81 $3K
OP279 <1% 327 $3K
82077 <1% 491 $3K
0001A <1% 93 $3K
0002A <1% 97 $3K
81003 <1% 1,009 $3K
84100 <1% 1,567 $3K
73130 <1% 89 $3K
OP370 <1% 14 $3K
80143 <1% 358 $2K
J2405 Injection, ondansetron hydrochloride, per 1 mg <1% 2,573 $2K
J1885 Injection, ketorolac tromethamine, per 15 mg <1% 2,488 $2K
90791 Psychiatric diagnostic evaluation <1% 44 $2K
72100 <1% 44 $2K
80179 <1% 327 $2K
A4215 Needle, sterile, any size, each <1% 527 $2K
76770 <1% 15 $2K
0064A <1% 66 $2K
J7030 Infusion, normal saline solution , 1000 cc <1% 3,264 $2K
87880 Infectious agent antigen detection by immunoassay; Streptococcus, group A <1% 325 $2K
84703 <1% 412 $2K
G0463 Hospital outpatient clinic visit for assessment and management of a patient <1% 49 $2K
82550 <1% 438 $2K
Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml <1% 138 $2K
77080 <1% 13 $2K
93971 <1% 14 $2K
J3490 Unclassified drugs <1% 2,945 $2K
93041 <1% 170 $1K
97165 <1% 42 $1K
87426 Infectious agent antigen detection, SARS-CoV-2 (COVID-19) <1% 118 $1K
96367 <1% 54 $1K
93970 <1% 12 $1K
90715 <1% 125 $1K
85027 <1% 433 $1K
0071A <1% 32 $1K
76705 Ultrasound, abdominal, real time with image documentation; limited <1% 12 $1K
0072A <1% 30 $1K
73562 <1% 30 $1K
99214 Doctor's office visit, returning patient (more involved) <1% 32 $1K
J1100 Injection, dexamethasone sodium phosphate, 1 mg <1% 926 $842.94
G1004 Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program <1% 5,874 $842.72
99213 Doctor's office visit, returning patient (routine) <1% 15 $831.75
83036 Hemoglobin; glycosylated (A1C) <1% 334 $794.83
90834 Psychotherapy session, about 45 minutes <1% 14 $759.52
80320 <1% 44 $729.95
J2704 Injection, propofol, 10 mg <1% 212 $708.64
76857 <1% 14 $628.00
73110 <1% 24 $612.59
G8979 Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting <1% 141 $609.04
J0696 Injection, ceftriaxone sodium, per 250 mg <1% 123 $561.09
74018 <1% 14 $505.42
G8978 Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals <1% 118 $502.17
J0131 Injection, acetaminophen, not otherwise specified,10 mg <1% 317 $494.13
Q0162 Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen <1% 219 $382.43
90471 Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine <1% 139 $355.11
83789 <1% 82 $352.34
80305 <1% 35 $332.64
82552 <1% 79 $307.81
G0279 Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) <1% 14 $285.64
J7050 Infusion, normal saline solution, 250 cc <1% 361 $282.18
87077 <1% 79 $167.31
87430 <1% 29 $143.72
J1170 Injection, hydromorphone, up to 4 mg <1% 178 $137.33
87186 <1% 45 $96.59
86140 <1% 57 $93.82
OP255 <1% 97 $89.89
J1200 Injection, diphenhydramine hcl, up to 50 mg <1% 249 $77.27
85652 <1% 97 $55.83
85379 <1% 13 $54.50
J7512 Prednisone, immediate release or delayed release, oral, 1 mg <1% 105 $43.60
83615 <1% 14 $38.64
J2060 Injection, lorazepam, 2 mg <1% 102 $36.23
87070 <1% 12 $27.90
J2270 Injection, morphine sulfate, up to 10 mg <1% 93 $26.76
J2765 Injection, metoclopramide hcl, up to 10 mg <1% 68 $17.00
Q0163 Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen <1% 37 $8.00
J2250 Injection, midazolam hydrochloride, per 1 mg <1% 13 $5.00
81002 <1% 27 $4.20
J3010 Injection, fentanyl citrate, 0.1 mg <1% 15 $0.85

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialWALTER, JOSEPH (SVP, CHIEF FINANCIAL OFFICER)
Same official

Other billing entities under WALTER, JOSEPH

Full network →
ProviderLocationPaid
Ahs Hospital Corp.Morristown, NJ$155.87M
Ahs Hospital Corp.Summit, NJ$125.20M
Ahs Hospital Corp.Pompton Plains, NJ$36.23M
Ahs Hospital CorpNewton, NJ$33.62M
Ahs Hospital Corp.Morristown, NJ$5.20M
Ahs Hospital Corp.Newton, NJ$4.82M
Ahs Hospital Corp.Newton, NJ$1.26M
Ahs Hospital CorpMorristown, NJ$171K
Ahs Hospital Corp.Morristown, NJ$1K
Ahs Hospital Corp.Morristown, NJ$1K
Ahs Hospital Corp.Morristown, NJ$708.57
Ahs Hospital CorpMorristown, NJ$149.55

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.